Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Chen-Hua LiuPo-Yueh ChenJyh-Jou ChenChing-Chu LoWei-Wen SuKuo-Chih TsengChun-Jen LiuChia-Sheng HuangKe-Jhang HuangSheng-Shun YangCheng-Yuan PengMing-Chang TsaiWei-Yu KaoChi-Yang ChangYu-Lueng ShihYu-Jen FangChi-Yi ChenPei-Lun LeeJow-Jyh HuangPei-Yuan SuChi-Wei TsengChien-Ching HungChung-Hsin ChangYi-Jie HuangHsueh-Chou LaiChun-Chao ChangFu-Jen LeeTsai‐Yuan HsiehJia-Horng Kao2026-01-302026-01-302021-03-0610.1007/s12072-021-10158-xhttps://scholars.csmu.edu.tw/handle/123456789/4134[SDGs]SDG3Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwanjournal-article